In The News: Department of Brain Health
In a new study from the University of Nevada, Las Vegas, researchers confirmed the link between type 2 diabetes and Alzheimer’s disease.
Eisai and Biogen announced that Eisai has initiated a rolling submission to the US Food and Drug Administration (FDA) of a Biologics License Application (BLA) for lecanemab (BAN2401), the company’s investigational anti-amyloid beta (Aß) protofibril antibody, for the treatment of early Alzheimer’s disease (early AD).
Optimistic about the drug’s efficacy, the company has initiated its submission for accelerated FDA approval.
A team of 51³Ô¹ÏºÚÁÏ neuroscientists has strengthened the link between Type II diabetes and Alzheimer's disease.
A team of 51³Ô¹ÏºÚÁÏ neuroscientists has strengthened the link between Type II diabetes and Alzheimer's disease.
A team of neuroscientists at 51³Ô¹ÏºÚÁÏ has reinforced the evidence for a link between type II diabetes and Alzheimer's disease.
A team of neuroscientists from the University of Nevada, Las Vegas-51³Ô¹ÏºÚÁÏ confirms the link between type II diabetes and Alzheimer's disease.
A team of 51³Ô¹ÏºÚÁÏ neuroscientists has strengthened the link between Type II diabetes and Alzheimer's disease.
A team of 51³Ô¹ÏºÚÁÏ neuroscientists has strengthened the link between Type II diabetes and Alzheimer’s disease.
A team of 51³Ô¹ÏºÚÁÏ neuroscientists has strengthened the link between Type II diabetes and Alzheimer’s disease.
A new program at 51³Ô¹ÏºÚÁÏ is addressing a critical healthcare shortage in the Las Vegas valley.
The occupational therapists in training at 51³Ô¹ÏºÚÁÏ will one day work with people recovering from strokes, injury — and COVID-19.